{"organizations": [], "uuid": "e544fe9c9a255046b17aad96ff593c2ef19c8c92", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180221.html", "section_title": "Archive News &amp; Video for Wednesday, 21 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-vertex-initiates-late-stage-study/brief-vertex-initiates-late-stage-study-of-treatment-combination-for-cystic-fibrosis-idUSASM000JKL", "country": "US", "domain_rank": 408, "title": "BRIEF-Vertex Initiates Late Stage Study Of Treatment Combination For Cystic Fibrosis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.344, "site_type": "news", "published": "2018-02-22T05:12:00.000+02:00", "replies_count": 0, "uuid": "e544fe9c9a255046b17aad96ff593c2ef19c8c92"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-vertex-initiates-late-stage-study/brief-vertex-initiates-late-stage-study-of-treatment-combination-for-cystic-fibrosis-idUSASM000JKL", "ord_in_thread": 0, "title": "BRIEF-Vertex Initiates Late Stage Study Of Treatment Combination For Cystic Fibrosis", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "vertex", "sentiment": "negative"}, {"name": "vertex pharmaceuticals inc", "sentiment": "negative"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 21 (Reuters) - Vertex Pharmaceuticals Inc:\n* VERTEX INITIATES FIRST PHASE 3 STUDY OF VX-659, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS\n* VERTEX PHARMACEUTICALS INC - GLOBAL PHASE 3 STUDY TO ENROLL 360 PATIENTS WITH ONE F508DEL MUTATION AND ONE MINIMAL FUNCTION MUTATION\n* VERTEX - PHASE 3 VX-659 STUDY DESIGNED TO SUPPORT SUBMISSION OF NDA IN U.S. BASED ON 4-WEEK PRIMARY EFFICACY ENDPOINT AND 12-WEEK SAFETY DATA Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T05:12:00.000+02:00", "crawled": "2018-02-22T17:57:01.016+02:00", "highlightTitle": ""}